Skip to main content
Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.630
-0.014 (-2.24%)
At close: Dec 5, 2025, 4:00 PM EST
0.603
-0.027 (-4.30%)
After-hours: Dec 5, 2025, 7:56 PM EST

Virax Biolabs Group Revenue

Virax Biolabs Group had revenue of $1.61K in the half year ending September 30, 2025, a decrease of -97.90%. This brings the company's revenue in the last twelve months to $2.99K, down -96.48% year-over-year. In the fiscal year ending March 31, 2025, Virax Biolabs Group had annual revenue of $6.33K, down -95.95%.

Revenue (ttm)
$2.99K
Revenue Growth
-96.48%
P/S Ratio
1,379.69
Revenue / Employee
$157
Employees
19
Market Cap
4.12M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 20256.33K-150.09K-95.95%
Mar 31, 2024156.42K147.86K1,727.11%
Mar 31, 20238.56K--
Mar 31, 2022---
Mar 31, 2021123.82K23.94K23.97%
Mar 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 435.16B
Johnson & Johnson 92.15B
Merck & Co. 64.24B
AbbVie 59.64B
Eli Lilly and Company 59.42B
AstraZeneca 58.13B
Novartis AG 56.37B
Novo Nordisk 49.58B
Revenue Rankings

VRAX News

More News